Pneumotox » Drug » Vedolizumab

Vedolizumab

2

Last update : 14/04/2021

I.a Pneumonitis (ILD), acute and/or severe (may cause ARDS)

1

I.b Pneumonitis (ILD)

1

I.c Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)

1

I.d Organizing pneumonia pattern (an area or areas of consolidation on imaging)

1

I.k Lung nodule or nodules

1

II.b ARDS - Acute lung injury

1

IV.c Obliterative bronchiolitis (a pattern consistent with) (see also IVn, XVx)

1

VIII.aq Bronchorrhea

1

X.g Hypersensitivity reaction (may manifest with fever and/or skin, throat or airway involvement)

1

X.o Neutrophilic dermatosis (Pyoderma, Sweet syndrome)

1

XV.b Path: Eosinophilic pneumonia (subacute or acute) (see also Ic)

1

XV.c Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)

1

XV.e Path: ILD with a granulomatous component (see also Im)

1

XV.x Path: Acute/subacute bronchiolitis (see also IVc, IVi)

1

XV.cn Path: Pulmonary necrotizing granuloma with neutrophilic microabscesses

1

XVI.g Imaging: Diffuse whiteout/alveolar shadowing (see also under IIb-ARDS)

1

XVI.v Imaging: Centrilobular micronodules (can be diffuse)

1

XVII.a Respiratory tract infection incl. pneumonia

1

XVII.v Strongyloides stercoralis hyperinfection (w/wo DAH)

1

Diagnosing DIRD

1

Drug and radiation history

2

Drug singularity - Correct identification of the drug

3

Consistent timing of exposure v. onset of symptoms

4

Clinical, imaging, BAL, pathological pattern consistent with the specific drug

5

Careful exlusion of another cause

6

Remission of symptoms with removal of drug

7

Recurrence with rechallenge (rarely advisable)

8

Causality assessment

More detailed checklist